Resources Archive - Page 11 of 97 - Amyloidosis Research Consortium

May 6, 2019

Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA

This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)

May 1, 2019

Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases

I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...

March 26, 2019

Advancing Amyloidosis: Roadmap for Research

FOR IMMEDIATE RELEASE LEADING EXPERTS PUBLISH A ROADMAP FOR CRITICAL AREAS OF RESEARCH IN AMYLOIDOSIS (more…)

March 12, 2019

ARC’s Advocates work Capitol Hill

Our ARC team of amyloidosis patients, caregivers and ARC staff took part as advocates in key activities during the week of Rare Disease Day, which is held on February 28th each year. (more…)

February 13, 2019

Join us for Rare Disease Week: Act Now!

Rare disease day takes place on February 28th of each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients. (more…)

Archives: Resources